Lilly Asia is looking to raise around US$180m via selling a 6% stake in CanSino Biologics Inc (6185 HK)'s H-shares. Lilly Asia last sold its stake in Apr 2020,
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.